Opinion on Pharmaceutical Manufacturers in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Novartis: Glivec en route to blockbuster status

According to recent research, newly diagnosed patients with chronic myeloid leukaemia are nine times more likely to achieve a complete cytogenetic response when treated with Novartis' [NVS] Glivec than when treated with traditional combination therapy. The continued positive results mean that Glivec looks set to become a blockbuster.

Published By Datamonitor
10 Jun 2003
CommentWire
CommentWire

Johnson & Johnson: contraceptive patch to shake up market

The continuing rollout of J&J's Evra marks an important development in the $4 billion hormonal contraception market. Oral pills have dominated the market for more than 40 years, but with competitive pricing, convenient dosing and the support of family planning organizations, the consumer friendly patch could shake everything up.

Published By Datamonitor
18 Jun 2003
CommentWire
CommentWire

ImClone Systems: Erbitux fortunes rally

The submission of Erbitux for marketing authorization in the European Union and Switzerland is the latest indication of a rally in ImClone Systems' [IMCL] fortunes following a rocky eighteen months. The European results also put ImClone's US licensing partner, Bristol Myers Squibb [BMY], a in a better position to try again for FDA approval.

Published By Datamonitor
16 Jul 2003
CommentWire
CommentWire

Roche: Bondronat gains additional indication

Roche's [ROCZ.S] bisphosphonate drug Bondronat has been recommended for the prevention of bone complications in patients with breast cancer and bone metastases by the EU advisory committee. Market authorization would significantly increase the drug's patient potential, but it is unlikely to threaten the supremacy of Novartis' [NVS] Zometa.

Published By Datamonitor
28 Jul 2003
CommentWire
CommentWire

Plant vaccines: growing closer to commercial reality

Transgenic plant technologies could lead to a revolution in vaccine production and manufacture. Should plant-based vaccines prove effective in clinical trials, this will drive licensing activity between key vaccine players and companies with relevant intellectual property.

Published By Datamonitor
20 Aug 2003
CommentWire
CommentWire

AstraZeneca: positive new data for Exanta and Atacand

Findings from three large-scale trials support the use of AstraZeneca's [AZN.L] new oral direct thrombin inhibitor, Exanta (ximelagatran), in post-MI and atrial fibrillation and the use of the angiotensin receptor blocker, Atacand (candesartan), in patients with heart failure. These results will further the company's stated aim to become the major cardiovascular player within the next five years.

Published By Datamonitor
04 Sep 2003
CommentWire
CommentWire

Bayer: too little, too late?

Bayer's [BAY.F] company structure has been modernized, with its conglomerate model streamlined to allow its four major components the freedom to operate independently and undergo M&A. However, the Healthcare division's portfolio is such that it may have trouble even finding a potential merger partner.

Published By Datamonitor
01 Oct 2003
CommentWire
CommentWire

Influenza: at-risk children need flu jabs

UK Department of Health figures show that the rate of illness in the under-four age group is three times higher than among middle-aged and elderly people. Despite this, fewer than half of the one million children in at-risk categories have been immunized. If successful, fresh attempts to improve the production process may be able to improve the levels of immunization among children.

Published By Datamonitor
04 Dec 2003
CommentWire
CommentWire

AstraZeneca: blockbuster status remains distant for Iressa

AstraZeneca's [AZN.L] Iressa was billed as one of a new class of anti-tumor agents that would revolutionize the treatment of lung cancer. However, to date the drug has been disappointing and approvals continue to be for third-line treatment. If Iressa is to reach blockbuster status, it must reach patients as a first line therapy.

Published By Datamonitor
05 Jan 2004

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.